First in class drug illustrates early signal of transport of key amyloid
marker from brain
TSX Exchange Symbol: RVX
CALGARY, Nov. 10 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that treatment with its lead drug RVX-208, a first in class ApoA-I/Prebeta-HDL elevating drug, in a post-hoc analysis from the Phase 1a clinical trial found that treatment with RVX-208 resulted in a positive trend on an important marker of cognitive function and Alzheimer's disease, Amyloid-beta40 is an important constituent of amyloid plaques in the brains of Alzheimer's patients. The analysis of the plasma markers for Alzheimer's disease was performed by Dr. D. Larry Sparks, Senior Scientist and Head of the Roberts Laboratory for Neurodegenerative Disease Research at Sun Health Research Institute in Sun City, Arizona.
The Phase 1a trial, a double-blind, dose-escalation, placebo-controlled trial enrolled 24 subjects in three separate dosing cohorts for a period of one week: 6 received placebo, and 6 received 2mg/kg per day, 6 received 3mg/kg per day and 6 received 8 mg/kg per day of RVX-208. Plasma levels of A-beta (A-beta40) were measured on day 1 and 7. A 12-14 percent increase in plasma A-beta40 levels was observed at the highest dose of RVX-208 after 7 days of dosing. Based on the study hypothesis these results trended towards significance versus placebo, even with the minimal number of study subjects.
Emerging evidence from large epidemiology studies such as the Harvard
Women's Study, the Honolulu-Asia Aging Study and the Whitehall II study
continue to build support for the relationship between poor HDL and ApoA-I
levels and decreased cognitive function and Alzheimer's disease. Dr.
Sparks's investigation of elective statin use and fractionated cholesterol
levels in the ADAPT cohort has identified a significant relationship
between elevated HDL levels and better performance on the Mini Mental State
|SOURCE Resverlogix Corp.|
Copyright©2008 PR Newswire.
All rights reserved